Replies to post #171098 on Biotech Values

[DewDiligence]

ENTA doesn't own the full combo, just part of combo. That's where $25k assumption came from.

No, my model’s $30K* number was the blended average US-and-EU price for ABBV’s entire 3-DAA regimen (excluding generic ribavirin, which costs very little).

*Not $25K, as previously posted.